Direct in vitro and in vivo comparison of (161)Tb and (177)Lu using a tumour-targeting folate conjugate (Q39338039)

11 September 2017

title

Direct in vitro and in vivo comparison of (161)Tb and (177)Lu using a tumour-targeting folate conjugate (English)

1 reference

11 September 2017

1 reference

2

1 reference

11 September 2017

8

1 reference

11 September 2017

Andreas Türler

7

0 references

author name string

Cristina Müller

1

1 reference

11 September 2017

Stephanie Haller

3

1 reference

11 September 2017

Holger Dorrer

4

1 reference

11 September 2017

Peter Bernhardt

5

1 reference

11 September 2017

Konstantin Zhernosekov

6

1 reference

11 September 2017

publication date

8 October 2013

1 reference

11 September 2017

number of pages

10

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

11 September 2017

volume

41

1 reference

11 September 2017

issue

3

1 reference

11 September 2017

page(s)

476-485

1 reference

Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2563-Z

Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2563-Z

Cerebral deafferentiation in operated gliomas as a predictor for malignancy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2563-Z

End-stage renal disease after treatment with 90Y-DOTATOC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2563-Z

Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2563-Z

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2563-Z

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2563-Z

A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β- radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2563-Z

In the book of life, the answers aren't in the back--Charlie Brown, fictional character of the Peanuts comic strip created by Charles Schulz.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2563-Z

DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2563-Z

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2563-Z

Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2563-Z

Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2563-Z

Dosimetric characterization of radionuclides for systemic tumor therapy: influence of particle range, photon emission, and subcellular distribution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2563-Z

In vivo radionuclide uptake quantification using a multi-pinhole SPECT system to predict renal function in small animals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2563-Z

Target burn-up corrected specific activity of 177Lu produced via 176Lu(n, gamma) 177Lu nuclear reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2563-Z

Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2563-Z

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate

21 January 2018

1 reference

12 December 2020

Evaluation in vitro and in rats of 161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy

1 reference

12 December 2020

Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters.

1 reference

12 December 2020

Production logistics of 177Lu for radionuclide therapy

1 reference

12 December 2020

Radiochemical separation of no-carrier-added 177Lu as produced via the 176Yb(n,gamma)177Yb-->177Lu process

1 reference

12 December 2020

The low-energy β− and electron emitter 161Tb as an alternative to 177Lu for targeted radionuclide therapy

1 reference

12 December 2020

ICRP Publication 107. Nuclear decay data for dosimetric calculations

1 reference

12 December 2020

Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide.

1 reference

12 December 2020

Yttrium-90 DOTATOC: first clinical results

1 reference

12 December 2020

Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate

1 reference

12 December 2020

10.1007/S00259-013-2563-Z

Identifiers

DOI

1 reference

11 September 2017

1 reference